[Endodermal sinus tumor--a contribution to the clinical aspects of ovarian tumors]. 1984

M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok

Two cases of endodermal sinus tumor (EST) are described in a 19-year-old girl and a 50-year-old menopausal women, respectively. Exstirpation uteri totalis cum adnexis was carried out in both cases. According to the FIGO the tumors were classified as Ic. The histologic diagnosis of EST was based on the presence of elements such as extraembryonic mesoderm, yolk sac mesoderm, vascular structures with Schiller-Duval bodies, PAS-positive globules in Duval sinus spaces. In the first case, where the proposed chemotherapy was refused, the patient died 4 months later with symptoms of abdominal metastases. In the other case, chemotherapy was applied according to the VAC program. At 13 months of the treatment a relaparotomy was made and the lymphatic nodes taken showed no metastases. Three months later, the tumor relapsed and the patient died at 22 months of the therapy. In the light of their observations and literature data the authors recommended a radical surgical intervention combined with intense polychemotherapy as the only effective approach to the problem.

UI MeSH Term Description Entries
D007044 Hysterectomy Excision of the uterus. Hysterectomies
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008649 Mesonephroma A rare tumor of the female genital tract, most often the ovary, formerly considered to be derived from mesonephric rests. Two varieties are recognized: (1) clear cell carcinoma, so called because of its histologic resemblance to renal cell carcinoma, and now considered to be of muellerian duct derivation and (2) an embryonal tumor (called also ENDODERMAL SINUS TUMOR and yolk sac tumor), occurring chiefly in children. The latter variety may also arise in the testis. (Dorland, 27th ed) Mesonephromas
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D002369 Castration Surgical removal or artificial destruction of gonads. Gonadectomy,Castrations,Gonadectomies
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271

Related Publications

M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
March 1984, Nihon Sanka Fujinka Gakkai zasshi,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
May 1996, Chinese medical journal,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
January 1984, Zentralblatt fur Gynakologie,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
February 2013, Journal of the Chinese Medical Association : JCMA,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
June 1989, Gynecologic oncology,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
August 2001, Gynecologic oncology,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
April 1986, Cancer,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
January 1977, American journal of obstetrics and gynecology,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
February 1977, American journal of obstetrics and gynecology,
M Cisło, and M Wawrzkiewicz, and Z Rzucidlo, and J Kornafel, and A Marczewski, and K Blok
July 1985, Chest,
Copied contents to your clipboard!